Full-Time
Director/Senior Director
Develops targeted cancer therapies using synthetic lethality
Mid, Senior, Expert
Dorchester, Boston, MA, USA
- At least 12-15 years' experience in total rewards and/or HR Systems, with a Bachelor's degree in a related field; advanced degree preferred
- Experience supporting the HR needs of a rapidly growing biotech organization
- Excellent problem solving and decision-making skills
- Significant knowledge of compensation systems and structures. Knowledge of Radford
- Experience in benefits management
- Excellent communication, teamwork, and leadership skills
- In partnership with the VP, Head Human Resources, you will maintain a compensation and leveling framework based on market and internal data (both Executive and Non-Executive)
- Partner with benefits brokers to design and implement comprehensive and competitive benefits plans
- Manage processes around other awards at Tango - spot bonus awards process, year-end awards, and milestone awards
- Working with resources like Radford and our compensation consultant, Pearl Meyer, provide strong, data driven insights to support compensation levels and the annual review process
- Lead the optimization of our HR Systems in partnership with other key stakeholders, such as IT and Finance
- Manage the annual salary survey and conduct market benchmarking to maintain competitiveness in the market
- Lead the compensation planning year-end and promotion process to completion and support staffing processes with a robust compensation partnership
- Understand the biotech environment in Boston to help support decisions around our compensation framework
- Lead the design of any needed incentive compensation structure as we enter the world of commercial
- Ensure pay equity and transparency standards for the organization
- Lead the work/content behind the Board of Directors Compensation Committee in partnership with the Head of Human Resources
- Additional duties and responsibilities as required
Tango Therapeutics, a biotechnology firm, stands out due to its unique approach to cancer treatment, utilizing advances in DNA sequencing and CRISPR-based target discovery to develop novel medicines targeting cancer vulnerabilities. The company's focus on synthetic lethality, a method that targets specific genes in cancer cells leaving normal cells largely unaffected, offers a potential for enhanced anti-tumor efficacy and reduced toxicity. Furthermore, Tango's patient-centric approach and deep understanding of genetic subtypes of cancer enable it to identify novel drug targets and combinations, accelerating the development of transformational new therapies for patients with well-defined populations currently lacking effective treatment options.
Company Stage
IPO
Total Funding
$537M
Headquarters
Boston, Massachusetts
Founded
2017